Analysts Set Aerie Pharmaceuticals Inc. (AERI) Price Target at $55.10
Aerie Pharmaceuticals Inc. (NASDAQ:AERI) has received a consensus rating of “Buy” from the eleven ratings firms that are covering the stock. One research analyst has rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $55.10.
AERI has been the subject of several recent analyst reports. Raymond James Financial Inc. initiated coverage on Aerie Pharmaceuticals in a research note on Tuesday, September 13th. They issued an “outperform” rating and a $48.00 target price for the company. Brean Capital restated a “buy” rating and issued a $48.00 target price on shares of Aerie Pharmaceuticals in a research note on Wednesday, September 7th. Needham & Company LLC restated a “buy” rating and issued a $45.00 target price on shares of Aerie Pharmaceuticals in a research note on Tuesday, August 23rd. RBC Capital Markets reiterated an “outperform” rating and issued a $55.00 price target (up previously from $51.00) on shares of Aerie Pharmaceuticals in a report on Friday, September 16th. Finally, Zacks Investment Research cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 4th.
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 37.75 on Thursday. The firm’s 50-day moving average is $36.84 and its 200-day moving average is $23.31. The stock’s market capitalization is $1.26 billion. Aerie Pharmaceuticals has a 52 week low of $10.82 and a 52 week high of $41.72.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). Analysts forecast that Aerie Pharmaceuticals will post ($2.84) earnings per share for the current fiscal year.
In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, October 6th. The stock was sold at an average price of $40.34, for a total transaction of $2,017,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 8.77% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in Aerie Pharmaceuticals during the third quarter worth $136,000. First Mercantile Trust Co. bought a new stake in Aerie Pharmaceuticals during the third quarter worth $161,000. Great West Life Assurance Co. Can bought a new stake in Aerie Pharmaceuticals during the third quarter worth $189,000. Geduld E E bought a new stake in Aerie Pharmaceuticals during the third quarter worth $226,000. Finally, Barclays PLC increased its stake in Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock worth $106,000 after buying an additional 200 shares during the last quarter. Institutional investors own 95.38% of the company’s stock.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.